Verici DX Plc Reaches a Global Licensing and Commercialisation Agreement with Thermo Fisher Scientific

Agreement grants rights to further develop an assay for pre-transplant prognostic testing.

CARDIFF, U.K. , November 15, 2023 / B3C newswire / -- Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, the world leader in serving science, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.

The exclusive license grants Thermo Fisher the rights to develop and offer an assay for pre-transplant risk assessment as a Laboratory Developed Test (“LDT”) in its CLIA laboratory in the U.S., as well as worldwide rights.

The aim is to develop a test that can risk stratify patients based on their likely immune response to a transplanted kidney and, as a result, enable clinicians to make more informed decisions about post-transplant and immunosuppressive management.

Commenting on the agreement, Sara Barrington, CEO of Verici Dx said: “We are incredibly proud of our advancements in transforming potential outcomes for kidney transplant patients. By collaborating with Thermo Fisher, we believe we can accelerate the development of our technology, helping ensure that it reaches those who need it the most.”

Nicole Brockway, President, Transplant Diagnostics, Thermo Fisher Scientific, said: “There is a significant need for effective tests that can identify the risk of transplant rejection early to help inform treatment decisions. Our hope is that this licensing agreement will allow us to develop a new prognostic assay that will expand and strengthen our portfolio of transplant testing solutions, demonstrating our commitment to enabling clinicians and improving the lives of patients throughout the pre- and post-transplant journey.”

About Verici Dx plc 
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Contacts

Verici Dx
Sara Barrington, CEO 
Julian Baines, Chairman
Via Walbrook PR
www.vericidx.com

Singer Capital Markets (Nominated Adviser & Broker)
Aubrey Powell / Sam Butcher / Jalini Kalaravy
+44 20 7496 3000

Walbrook PR Limited
Paul McManus / Sam Allen
T +44 20 7933 8780
M +44 7980 541 893 / +44 7502 558 258
vericidx@walbrookpr.com

Keywords: Humans; Prognosis; Organ Transplantation; Kidney Transplantation; Risk Assessment; Immunity; Licensure; Pathology, Molecular; RNA;  Transcriptome; Artificial Intelligence; United Kingdom

Published by B3C newswire